Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
The return on assets (ROA) is N/A as of Tuesday, October 6, 2026.
RETURN ON ASSETS (ROA)
N/A
Veraxa Biotech Holding AG
Market Cap
$152.72M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$153.58M
Return on Assets (ROA)
N/A
TTM Avg
-34.95%
3Y Avg
-49.76%
5Y Avg
-43.08%
Market Cap
$153.79M
Return on Assets (ROA)
-23.14%
TTM Avg
-29.29%
3Y Avg
-29.10%
5Y Avg
-28.90%
Market Cap
$151.01M
Return on Assets (ROA)
-127.14%
TTM Avg
-129.15%
3Y Avg
-91.50%
5Y Avg
-82.73%
Market Cap
$149.36M
Return on Assets (ROA)
-50.30%
TTM Avg
-131.74%
3Y Avg
-92.52%
5Y Avg
-67.08%
Market Cap
$156.22M
Return on Assets (ROA)
-8.61%
TTM Avg
-9.87%
3Y Avg
-17.96%
5Y Avg
-12.40%
Market Cap
$148.73M
Return on Assets (ROA)
-96.78%
TTM Avg
-33.63%
3Y Avg
-87.61%
5Y Avg
-84.15%
Market Cap
$148.64M
Return on Assets (ROA)
-54.48%
TTM Avg
-32.00%
3Y Avg
-13.86%
5Y Avg
-13.02%
Market Cap
$148.27M
Return on Assets (ROA)
-20.01%
TTM Avg
-38.20%
3Y Avg
-34.64%
5Y Avg
-39.69%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Veraxa Biotech Holding AG (VRXA) | $152.72M | N/A | N/A | N/A | N/A |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | N/A | -34.95% | -49.76% | -43.08% |
| Neuronetics, Inc. (STIM)vs › | $153.79M | -23.14% | -29.29% | -29.10% | -28.90% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $151.01M | -127.14% | -129.15% | -91.50% | -82.73% |
| ALX Oncology Holdings Inc. (ALXO)vs › | $149.36M | -50.30% | -131.74% | -92.52% | -67.08% |
| Inogen, Inc. (INGN)vs › | $156.22M | -8.61% | -9.87% | -17.96% | -12.40% |
| Korsana Biosciences, Inc. (KRSA)vs › | $148.73M | -96.78% | -33.63% | -87.61% | -84.15% |
| Voyager Therapeutics, Inc. (VYGR)vs › | $148.64M | -54.48% | -32.00% | -13.86% | -13.02% |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | -20.01% | -38.20% | -34.64% | -39.69% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | -90.55% | -70.80% | -45.07% | -40.08% |
ROA
N/A
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
